SARS-CoV-2-associated gut microbiome alteration; A new contributor to colorectal cancer pathogenesis.

The emergence of a novel coronavirus, COVID-19, in December 2019 led to a global pandemic with more than 170 million confirmed infections and more than 6 million deaths (by July 2022). Studies have shown that infection with SARS-CoV-2 in cancer patients has a higher mortality rate than in people without cancer. Here, we have reviewed the evidence showing that gut microbiota plays an important role in health and is linked to colorectal cancer development. Studies have shown that SARS-CoV-2 infection leads to a change in gut microbiota, which modify intestinal inflammation and barrier permeability and affects tumor-suppressor or oncogene genes, proposing SARS-CoV-2 as a potential contributor to CRC pathogenesis.

Human Responses in Public Health Emergencies for Infectious Disease Control: An Overview of Controlled Topologies for Biomedical Applications.

COVID-19 originated in Wuhan city of Hubei Province in China in December three years ago. Since then, it has spread to more than 210 countries and territories. This disease is caused by Severe Acute Respiratory Syndrome Coronavirus 2. The virus has a size of one to two nanometers and a single-stranded positive RNA. Droplets spread the virus from coughing and sneezing. This condition causes coughing, fever, acute respiratory problems, and even death. According to the WHO, the virus can survive outside the body for several hours. This research aimed to determine how environmental factors influenced the COVID-19 virus's survival and behavior, as well as its transmission, in a complex environment. Based on the results, virus transmissions are influenced by various human and environmental factors such as population distribution, travel, social behavior, and climate change. Environmental factors have not been adequately examined concerning the transmission of this epidemic. Thus, it is necessary to examine various aspects of prevention and control of this disease, including its effects on climate and other environmental factors.

Clinical characteristics of 200 COVID-19 patients in Mashhad, Iran, February and March 2020.

Introduction: Coronavirus disease 2019 (COVID-19) is a pulmonary involvement which was reported for the first time in December 2019 in the city of Wuhan, Hubei province, China. The aim of the study was to describe the demographic, clinical, laboratory, and radiological characteristics of 204 definitive laboratory-confirmed COVID-19 patients hospitalized in Mashhad, Khorasan Razavi province, Iran. Patients and Methods: This study was performed on 204 laboratory-confirmed COVID-19 patients. A set of laboratory tests combined with various patient information and results from lung high-resolution computed tomography (HRCT) were gathered in a checklist and analyzed to give us a better view of patients who are hospitalized due to the complications caused by this disease. Results: The average age of our patients was 58.83 ± 15.93 years. There were 122 (59.8%) male and 82 (40.2%) female patients, and almost all of our patients had at least one underlying disease. Nine (4.4%) of our patients reported having gone for a trip to COVID-19-epidemic areas in the last 2 weeks. The most common signs shared among all our patients were cough, fever, and decreased O2 saturation; the average respiratory rate was 25.50 ± 6.74/min, average axillary body temperature was 37.69°C ± 0.69°C, and average O2 saturation was 88.34% ± 7.34%. Conclusion: Based on our results, the most common signs of this disease are fever, cough, and shortness of breath, similar to seasonal influenza. Our data on disease severity showed that 33 (16.2%) patients had moderate disease, 139 (68.1%) had severe disease, and 28 (13.7%) were critical; 22 (10.8%) of our hospitalized patients died due to the complications of this disease.

A review of the effect of COVID-19 on immune responses of the body.

After the world faced the epidemic of COVID-19 caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), novel clinical evidence and genetics related to this virus are emerging. This virus presents a broad range of clinical manifestations that mainly include various asymptomatic infections and severe pneumonia that are followed by multiple organ failures which could lead to death. The immune system has a critical role in the protection of the body against viruses and diseases and the production of antibodies against pathogens. The present study aimed to investigate the effect of COVID-19 on immune responses of the body. A comprehensive collection of related clinical trials and reviews on the issue of COVID-19 were searched. The main focus of the reviewed studies was on immune response in COVID-19. In this regard, various databases of PubMed, EMBASE, Scopus, CINAHL Plus, Cochrane Library, and Google Scholar were reviewed and all related articles from 2010 to 2021 were investigated. All records were searched in the English language and finally records with the highest thematic relevance were included in the main criteria of the study. It is well-known that the immune system's response to the SARS-CoV-2 virus involves all the components of the immune system that are responsible for viral elimination and recovery of the body. However, these immune system responses are involved in the progression of COVID-19 to a severe and lethal process. When the period of COVID-19 in the body increases, the regulation between protective and altered responses will be lost because of exacerbation of the inflammatory components. Therefore, all the responsible factors which affect immunity should be investigated just like that performed in this study.

Clinical features and disease severity in an Iranian population of inpatients with COVID-19.

Coronavirus disease 2019 (COVID-19) can present with a variety of symptoms. Severity of the disease may be associated with several factors. Here, we review clinical features of COVID-19 inpatients with different severities. This cross-sectional study was performed in Imam Reza hospital, Mashhad, Iran, during February-April 2020. COVID-19 patients with typical computed tomography (CT) patterns and/or positive reverse-transcriptase polymerase chain reaction (RT-PCR) were included. The patients were classified into three groups of moderate, severe, and critical based on disease severity. Demographic, clinical, laboratory, and radiologic findings were collected and compared. P < 0.05 was considered statistically significant. Overall, 200 patients with mean age of 69.75 ± 6.39 years, of whom 82 (41%) were female were studied. Disease was severe/critical in the majority of patients (167, 83.5%). Disease severity was significantly associated with age, malignant comorbidities, dyspnea, nausea/vomiting, confusion, respiratory rate, pulse rate, O2 saturation, extent of CT involvement, serum C-reactive protein (CRP), pH, pO2, and aspartate transaminase (P < 0.05). Moreover, complications including shock, coagulopathy, acidosis, sepsis, acute respiratory distress syndrome (ARDS), intensive care unit (ICU) admission, and intubation were significantly higher in patients with higher severities (P < 0.05). O2 saturation, nausea/vomiting, and extent of lung CT involvement were independent predictors of severe/critical COVID-19 (OR 0.342, 45.93, and 25.48, respectively; P < 0.05). Our results indicate O2 saturation, nausea/vomiting, and extent of lung CT involvement as independent predictors of severe COVID-19 conditions. Serum CRP levels and pO2 were also considerably higher patients with higher severity and can be used along with other factors to predict severe disease in COVID-19 patients.